Download MendeleyExploration of the P1 residue in 3CL protease inhibitors leading to the discovery of a 2-tetrahydrofuran P1 replacement.
Barton, L.S., Callahan, J.F., Cantizani, J., Concha, N.O., Cotillo Torrejon, I., Goodwin, N.C., Joshi-Pangu, A., Kiesow, T.J., McAtee, J.J., Mellinger, M., Nixon, C.J., Padron-Barthe, L., Patterson, J.R., Pearson, N.D., Pouliot, J.J., Rendina, A.R., Buitrago Santanilla, A., Schneck, J.L., Sanz, O., Thalji, R.K., Ward, P., Williams, S.P., King, B.W.(2024) Bioorg Med Chem 100: 117618-117618
- PubMed: 38309201
- DOI: https://doi.org/10.1016/j.bmc.2024.117618
- Primary Citation of Related Structures:
8UHO, 8UIA, 8UIF, 8ULD - PubMed Abstract:
The virally encoded 3C-like protease (3CL pro ) is a well-validated drug target for the inhibition of coronaviruses including Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Most inhibitors of 3CL pro are peptidomimetic, with a γ-lactam in place of Gln at the P1 position of the pseudopeptide chain. An effort was pursued to identify a viable alternative to the γ-lactam P1 mimetic which would improve physicochemical properties while retaining affinity for the target. Discovery of a 2-tetrahydrofuran as a suitable P1 replacement that is a potent enzymatic inhibitor of 3CL pro in SARS-CoV-2 virus is described herein.
Organizational Affiliation:
GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, United States. Electronic address: linda.s.barton@gsk.com.
